10-K: Calidi Biotherapeutics Outlines Capital Structure and Growth Strategy in 10-K Filing

Calidi Biotherapeutics details its capital structure, stock options, warrants, and strategic plans for advancing its immuno-oncology pipeline in its annual 10-K filing.

Summary

• Calidi Biotherapeutics, a clinical-stage immuno-oncology company, has filed its annual 10-K report, outlining its capital structure and strategic plans.
• The company's authorized capital stock consists of 331 million shares, including 330 million common shares and 1 million preferred shares.
• As of March 8, 2024, there were 53,538,034 shares of common stock outstanding, 11,500,000 public warrants, and 1,912,154 private placement warrants.
• The company is developing proprietary allogeneic stem cell-based platforms and enveloped vaccinia virus platforms to deliver oncolytic viruses to cancer patients.
• Calidi is advancing three clinical development programs: CLD-101 for newly diagnosed and recurrent high-grade glioma, and CLD-201 for advanced solid tumors.
• The company is also engaged in early discovery research for CLD-400 for certain lung cancers and metastatic solid tumors, and CLD-301 for multiple indications.
• Calidi has a licensing agreement with Northwestern University for the commercialization rights to CLD-101 and a license agreement with the University of Chicago for patents covering cancer therapies using an oncolytic adenovirus in combination with a clinical grade allogeneic neural stem cell line.
• The company is also collaborating with Personalized Stem Cells, Inc. for a Covid-19 therapeutic candidate.
• Calidi is subject to extensive regulations by the FDA and other regulatory authorities, and the process of obtaining regulatory approvals is lengthy and expensive.
• The company is also subject to various healthcare laws and regulations, including anti-kickback, false claims, and patient data privacy laws.
• Calidi has a limited operating history and has not generated any revenue to date from product sales, and anticipates continued losses for the foreseeable future.
• The company needs to raise substantial additional funding and may be forced to delay, reduce or eliminate some of its product development programs if it is unable to raise capital when needed.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has a promising technology and pipeline, it faces significant financial challenges and regulatory hurdles. The lack of revenue and the need for substantial additional funding are major concerns.

Positives

• Calidi is developing innovative stem cell-based and enveloped platforms for the delivery and potentiation of oncolytic viruses.
• The company has multiple product candidates in its pipeline, targeting various types of cancer.
• Calidi has secured licensing agreements with Northwestern University and the University of Chicago for key technologies.
• The company has a collaboration agreement with Personalized Stem Cells, Inc. for a Covid-19 therapeutic candidate.
• The company has a Standby Equity Purchase Agreement with Yorkville for up to $25 million of its shares of common stock.
• The company has a strong in-house process development capabilities for oncolytic viruses cell banks and combinatory products.

Negatives

• Calidi has a limited operating history and has not generated any revenue to date from product sales.
• The company anticipates continued losses for the foreseeable future.
• Calidi needs to raise substantial additional funding and may be forced to delay, reduce or eliminate some of its product development programs if it is unable to raise capital when needed.
• The company is subject to extensive regulations by the FDA and other regulatory authorities, and the process of obtaining regulatory approvals is lengthy and expensive.
• The company is subject to various healthcare laws and regulations, including anti-kickback, false claims, and patient data privacy laws.
• The company is dependent on third parties for manufacturing and clinical trials.

Risks

• The company has a limited operating history and has not generated any revenue to date from product sales.
• The company anticipates continued losses for the foreseeable future.
• The company needs to raise substantial additional funding and may be forced to delay, reduce or eliminate some of its product development programs if it is unable to raise capital when needed.
• The company is subject to extensive regulations by the FDA and other regulatory authorities, and the process of obtaining regulatory approvals is lengthy and expensive.
• The company is subject to various healthcare laws and regulations, including anti-kickback, false claims, and patient data privacy laws.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company faces competition from major pharmaceutical, specialty pharmaceutical and biotechnology companies.
• The company's product candidates may not achieve broad market acceptance, which would limit the revenue that it generates from their sales.
• The company's product candidates may not be safe or effective.
• The company may not be able to protect its intellectual property.
• The company's stock price may be volatile.

Future Outlook

The company anticipates advancing three clinical development programs over the next 6-24 months and expects to continue to incur significant expenses and operating losses for the foreseeable future.

Industry Context

The company operates in the competitive immuno-oncology market, facing competition from major pharmaceutical and biotechnology companies, as well as other companies developing viral immunotherapies.

Comparison to Industry Standards

• The company's approach of using allogeneic stem cells and enveloped viruses for oncolytic virus delivery is a novel approach that differs from many other companies in the field.
• The company's use of allogeneic stem cells is intended to address the limitations of autologous stem cell therapies, such as scalability and patient compliance.
• The company's enveloped virus platform is intended to address the rapid elimination of oncolytic viruses by the patients immune system, a common challenge in the field.
• The company's focus on systemic delivery to target metastatic cancer is aligned with the growing need for effective treatments for advanced disease.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a lawsuit with former physicians regarding stock options, which was settled on February 9, 2024.
• The company is involved in a lawsuit with its former chief accounting officer and interim chief financial officer, alleging constructive discharge and defamation.
• The company entered into a settlement agreement with an investor who previously entered into a series of related agreements for the purpose of satisfying the Minimum Cash Condition required under the Business Combination.

Related Party Transactions

• The company has engaged in various transactions with related parties, including loans, stock issuances, and consulting agreements.
• The company has entered into a lease agreement with a related party, where the related party provided a personal guaranty of lease.
• The company has entered into a consulting agreement with a related party.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of additional shares of common stock.
• Shareholders may experience volatility in the stock price.
• Employees may be affected by changes in compensation and benefits.
• Customers may be affected by delays in product development and commercialization.
• Creditors may be affected by the company's ability to repay its debts.
• Suppliers may be affected by the company's ability to pay for goods and services.

Next Steps

• The company plans to commence a Phase 1b clinical trial for CLD-101 in collaboration with Northwestern University in the first half of 2024.
• The company anticipates commencing a Phase 1 clinical trial for CLD-201 during the second half of 2024.
• The company intends to explore combination therapy studies using its platforms in conjunction with other immunotherapies.
• The company intends to pursue collaborations and out-license opportunities for continued development of its AAA cell bank for non-cancer indications.

Key Dates

Keywords

immuno-oncology, oncolytic viruses, stem cell therapy, cancer treatment, clinical trials, biotechnology, drug development, capital structure, warrants, intellectual property